stoxline Quote Chart Rank Option Currency Glossary
  
Royalty Pharma plc (RPRX)
27.645  -0.175 (-0.63%)    04-23 11:14
Open: 27.84
High: 27.84
Volume: 1,225,935
  
Pre. Close: 27.82
Low: 27.22
Market Cap: 12,349(M)
Technical analysis
2024-04-23 10:50:50 AM
Short term     
Mid term     
Targets 6-month :  34.37 1-year :  35.97
Resists First :  29.43 Second :  30.79
Pivot price 28.45
Supports First :  27.21 Second :  22.64
MAs MA(5) :  27.75 MA(20) :  28.86
MA(100) :  28.99 MA(250) :  29.63
MACD MACD :  -0.7 Signal :  -0.5
%K %D K(14,3) :  13.7 D(3) :  15.2
RSI RSI(14): 31.9
52-week High :  35.75 Low :  25.92
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RPRX ] has closed above bottom band by 10.3%. Bollinger Bands are 30.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 28.42 - 28.56 28.56 - 28.67
Low: 27.34 - 27.5 27.5 - 27.61
Close: 27.58 - 27.83 27.83 - 28.03
Company Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Headline News

Tue, 23 Apr 2024
abrdn plc Sells 2,448,301 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Sat, 20 Apr 2024
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 - Yahoo Finance

Fri, 19 Apr 2024
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 - Barron's

Thu, 18 Apr 2024
Royalty Pharma plc (NASDAQ:RPRX) Plans Quarterly Dividend of $0.21 - MarketBeat

Tue, 16 Apr 2024
RPRX: 3 Biotech Stocks to Watch for Lucrative Gains - StockNews.com

Thu, 04 Apr 2024
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 447 (M)
Shares Float 384 (M)
Held by Insiders 3.8 (%)
Held by Institutions 72 (%)
Shares Short 12,390 (K)
Shares Short P.Month 13,130 (K)
Stock Financials
EPS 2.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 14.6
Profit Margin 48.2 %
Operating Margin 102.8 %
Return on Assets (ttm) 5.6 %
Return on Equity (ttm) 17.3 %
Qtrly Rev. Growth 5.4 %
Gross Profit (p.s.) 0
Sales Per Share 5.26
EBITDA (p.s.) 3.35
Qtrly Earnings Growth 0 %
Operating Cash Flow 2,990 (M)
Levered Free Cash Flow -1,250 (M)
Stock Valuations
PE Ratio 10.78
PEG Ratio 2.2
Price to Book value 1.86
Price to Sales 5.18
Price to Cash Flow 4.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android